Aegle Raises $4M to Fund First Phase 1/2 Trial of Experimental Therapy AGLE-102 for DEB
News
Aegle Therapeutics has raised $4 million to fund the first clinical trial evaluating AGLE-102, a therapy candidate for people with dystrophic epidermolysis bullosa (DEB) based on the company’s extracellular ... Read more